Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
NHLBI Catalyze grants fund platform technologies to accelerate the development of diagnostics and therapeutics for heart, lung, blood, and sleep disorders.
Funder: National Institutes of Health
Due Dates: February 11, 2027 (Applications) | June 17, 2027 (Applications) | October 21, 2027 (Applications) | December 23, 2027 (Opportunity closing)
Funding Amounts: Up to $350,000 in direct costs per year for up to two years; no cost sharing required
Summary: Supports development and rigorous validation of transformative, multi-use technologies and platforms for heart, lung, blood, and sleep research.
Key Information: Major feasibility gaps must already be overcome, supported by preliminary data; clinical trials are not allowed.
Description
The National Heart, Lung, and Blood Institute (NHLBI) administers this R33 opportunity within its Catalyze innovation program. It supports further development and rigorous validation of enabling technologies and transformative platforms for next-generation predictive, diagnostic, and therapeutic products or model systems relevant to heart, lung, blood, and sleep (HLBS) disorders.
Projects should establish repeatable, reliable performance in an HLBS-relevant biological or clinical system, rather than pursue a specific biological discovery or disease-specific efficacy demonstration. Technologies must offer substantially improved or qualitatively new capabilities, with potential to transform screening, model development, diagnosis, treatment, prevention, or epidemiology. Responsive work includes novel materials, reagents, instrumentation, devices, and associated methods and models. The broader Catalyze program helps move basic discoveries toward product development while building researchers’ product-development and entrepreneurship skills.
